Doxorubicinone Valerate
- CAS NO.:158699-93-5
- Empirical Formula: C26H26O10
- Molecular Weight: 498.48
- Update Date: 2022-12-21 16:56:50
What is Doxorubicinone Valerate?
The Uses of Doxorubicinone Valerate
Doxorubicinone Valerate is a related compound of?Doxorubicin Hydrochloride (D558000), an antineoplastic used to treat a wide range of cancers.
Properties of Doxorubicinone Valerate
Boiling point: | 742.3±60.0 °C(Predicted) |
Density | 1.481±0.06 g/cm3(Predicted) |
pka | 7.44±0.60(Predicted) |
Safety information for Doxorubicinone Valerate
Computed Descriptors for Doxorubicinone Valerate
New Products
COBALT AAS SOLUTION HYDROXYLAMINE HYDROCHLORIDE SOLUTION 10% THOMALIT BLUE LITMUS PAPER 1 BOX SILVER NITRATE N/10 CVS GLASS BEADS 3.5 TO 4.5 MM POTASSIUM AAS SOLUTION Azithromycin Imp D Atracurium Besylate EP Impurity C Ceftaroline fosamil Acetate Hydrate Clarithromycin EP impurity F Clarithromycin EP Impurity D Clindamycin BRelated products of tetrahydrofuran
Epirubicin hydrochloride
(8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxynaphthacene-5,12-dione hydrochloride
8-Desacetyl-8-carboxy Daunorubicin Hydrochloride
N-trifluoroacetyladriamycin
11-Deoxydaunorubicin HCl
7,8,9,10-Dehydro Doxorubicinone
Doxorubicin Impurity 15
14-Hydroxy Carminomycin
You may like
-
Atracurium Besylate EP Impurity CView Details
86293-35-8 -
Atracurium Besylate EP Impurity DView Details
87046-72-8 -
Azithromycin EP Impurity CView Details
620169-47-3 -
Azithromycin Imp DView Details
612069-26-8 -
Ceftaroline fosamil Acetate HydrateView Details
400827-55-6 -
Clarithromycin EP Impurity FView Details
128940-83-0 -
Clarithromycin EP Impurity DView Details
101666-68-6 -
Clindamycin Impurity BView Details
18323-43-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.